ERBB2 and triple-negative breast carcinoma: There is a large variation in survival after diagnosis of BM that ranges from Triple Negative Breast Cancer (TNBC), with a median survival of 4–5 months, to Human Epidermal growth factor Receptor 2 (HER2) positive (HER2+) BC with a median survival following BM diagnosis of 9–16 months3,4.